Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus

Main Article Content

Andrew Blauvelt
Oregon Medical Research Center

Zoe D. Draelos
Dermatology Consulting Services

Melinda Gooderham
SKiN Centre for Dermatology, Probity Medical Research and Queen’s University

Edward Lain
Sanova Dermatology

Angela Y. Moore
Arlington Research Center and Baylor University Medical Center

Kim A. Papp
Probity Medical Research and K Papp Clinical Research

Matthew Zirwas
Dermatologists of the Central States, Probity Medical Research, and Ohio University

David Krupa
Arcutis Biotherapeutics, Inc.

Patrick Burnett
Arcutis Biotherapeutics, Inc.

David R. Berk
Arcutis Biotherapeutics, Inc.

David H. Chu
Arcutis Biotherapeutics, Inc.

Keywords

Seborrheic Dermatitis, roflumilast, phosphodiesterase 4 inhibitor

References

1. Peyrí J, et al. Actas Dermosifiliogr 2007;98:476–482.

2. Borda LJ, et al. J Clin Investig Dermatol 2015;3:10.13188/2373-1044.1000019.

3. Dessinioti C, et al. Clin Dermatol 2013;31:343–351.

4. Tucker D, Masood S. Seborrheic dermatitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.

5. Zirwas M, et al. Poster presented at: 30th Congress of the European Academy of Dermatology and Venereology (EADV) Virtual, September 29– October 2, 2021.

6. Berger RS, Bowman JP. J Toxicol Cut Ocular Toxicol 1982;1:109–115.

Article Sidebar

Poster PDF
Published
Jul 17, 2023
DOI https://doi.org/10.25251/skin.7.supp.226

Article Details

How to Cite
[1]
Blauvelt, A., Draelos, Z.D., Gooderham, M., Lain, E., Moore, A.Y., Papp, K.A., Zirwas, M., Krupa, D., Burnett, P., Berk, D.R. and Chu, D.H. 2023. Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus. SKIN The Journal of Cutaneous Medicine. 7, 4 (Jul. 2023), s226. DOI:https://doi.org/10.25251/skin.7.supp.226.
Issue
Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23
Section
Seborrheic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>